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Abstract  
Background: 
The Charlson index is a widely used measure of comorbidity.  The objective was to compare 
Charlson index scores calculated using administrative data to those calculated using case-
note review in relation to all-cause mortality and initiation of renal replacement therapy in a 
Scottish chronic kidney disease cohort (GLOMMS-1).  
Methods: 
Modified Charlson index scores were calculated using both data sources in the GLOMMS-1 
cohort. Agreement between scores was assessed using the weighted Kappa. The association 
with outcomes was assessed using Poisson regression and the performance of each was 
compared using net reclassification improvement. 
Results: 
Of 3,382 individuals, median age 78.5 years, 56% female, there was moderate agreement 
between scores derived from the two data sources (weighted kappa 0.41). Both scores were 
associated with mortality independent of a number of confounding factors. Administrative 
data Charlson scores were more strongly associated with death than case-note review 
scores using net reclassification improvement. Neither score was associated with 
commencing renal replacement therapy. 
Conclusion: 
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Despite only moderate agreement, modified Charlson index scores from both data sources 
were associated with mortality. Neither was associated with commencing renal replacement 
therapy. Administrative data compared favourably and may be superior to case-note review 
when used in the Charlson index to predict mortality. 
Key words: Administrative data, Case-mix, Chronic Disease, Comorbidity 
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Introduction 
Comorbidity, the burden of disease co-existing with a particular disease of interest, is having 
an increasing impact upon our health services as our population ages and the prevalence of 
chronic disease increases.1,2 It affects the course and outcome of disease or illness, is costly 
to health and social care services and is an important confounding factor as well as being 
predictive of outcomes.1,3-7 Consequently, accurately adjusting for its impact is an important 
aspect of health services research as well as providing information for the assessment for 
case-mix and supporting individual patient care planning including prognosis.8  
The Charlson comorbidity index is a widely used measure of comorbidity developed over 20 
years ago to predict one-year mortality in a cohort of medical inpatients.9 Since then it has 
been used in many populations with a variety of outcomes.4,10-17 An overall score is 
calculated from a list of conditions, each of which has been allocated a weight of between 
one and six based upon its adjusted relative risk of one-year mortality.9  
The Charlson index was originally developed using case-note review (CNR) data, often 
considered the gold-standard method of assessing comorbidity.4 However, it is resource 
intensive and consequently the index has been adapted for use with routine administrative 
datasets.18,19 Despite this, there remains uncertainty about the appropriateness of its 
application to administrative data. Previous studies comparing the methodological 
approaches have produced conflicting results, which may be related to the heterogeneous 
populations studied and also to their relatively small sample sizes.5,13,20-25  The majority of 
studies have assessed populations of less than 1,0005,21,23-25 and the largest study was 1,989 
cardiovascular patients in Canada.20 
 7 
 
The Grampian Laboratory Outcomes Mortality and Morbidity Study (GLOMMS-1) cohort is a 
sample of over 3,000 individuals with impaired renal function and provides a valuable 
opportunity to compare case-note reviewCNR and administrative data Charlson scores in a 
large population. The aim of this study was to compare Charlson scores calculated using 
administrative data to those calculated using case-note reviewCNR data and explore the 
impact of these methods on the association with all-cause mortality and initiation of renal 
replacement therapy (RRT). 
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Method 
Setting and study population  
In 2003, a study was set up to explore outcomes in adults aged over 15 years with abnormal 
renal function (serum creatinine ≥150µmol/l for males and ≥130µmol/l for females) resident 
in the National Health Service (NHS) Grampian administrative region in the North-East of 
Scotland. NHS Grampian is one of 14 regional Health Boards in Scotland and provides 
medical services to a defined population (n= 433, 109 aged over 15 in 2003). 
Chronic Kidney Disease (CKD) is commonly classified in five stages based upon evidence of 
kidney damage and the glomerular filtration rate. Increasing stage indicates increasing 
severity.26 The GLOMMS-1 cohort, used in this study, included only those who met the 
definition of CKD based upon an estimated glomerular filtration rate of less than 
60ml/min/1.73m2 for 90 days. The long term outcomes are described elsewhere.27  Patients 
not meeting the definition of CKD and those on RRT at index date (the date of the first 
qualifying raised creatinine measurement during the period 1st January to 30th June 2003) 
were excluded.  
The GLOMMS-1 cohort contained 3,426 individuals aged over 15 with stage three to five 
CKD sourced from 433,109 individuals aged over 15 within theliving in NHS Grampian 
administrative region in 2003. After excluding 12 patients who died on the index date, and 
32 patients who could not be linked to their administrative data, the study population 
available for analysis from baseline was 3,382. The cohort was followed-up for six years. Of 
the survivors, only 51 had no contact with NHS Grampian within one year of the end of the 
study. 
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Available variables 
Data on baseline comorbid conditions, smoking status and postcodes (allowing 
identification of the Scottish Index of Multiple Deprivation status of individuals) were 
extracted by case-note reviewCNR in 2003. The presence of protein in the urine is a sign of 
kidney injury. Baseline proteinuria status was based upon the single most recentlatest 
measurement of protein in the urine from 1999 to index date.26 
The GLOMMS-1 cohort was linked to NHS Grampian hospital episode data through 
deterministic matching using the Community Health Index number (a unique patient 
identifier used throughout the Scottish healthcare system). Scottish hospital administrative 
data are held centrally by the Information Services Division, and coded using the World 
Health Organization’s International Classification of Disease version 10 (ICD-10) tool. 
General acute inpatient and day case episodes are held in the form of Scottish Morbidity 
Record (SMR) 01 administrative data.  
The GLOMMS-1 cohort was linked to three datasets through deterministic matching using 
the Community Health Index number (a unique patient identifier used throughout the 
Scottish healthcare system) in order to ascertain administrative data comorbidity 
information, RRT status and mortality status. These datasets were the local renal 
management system, the NHS Grampian-held National Records of Scotland data and the 
NHS Grampian-held Scottish Morbidity Record (SMR) 01 administrative data. The National 
Records of Scotland provide mortality data. SMR01 is an episode-based patient record 
relating to all hospital general acute inpatient and day case stays. Diagnoses are recorded on 
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discharge using the World Health Organization’s International Classification of Disease 
version 10 (ICD-10) tool.  
The SMR01 administrative data included conditions coded as a primary diagnosis or as an 
additional diagnosis on discharge.  
 
Charlson comorbidity index 
Case-note reviewCNR and data linkage were carried out for the purpose of another study 
and not with the primary intention of calculating the Charlson index. Therefore due to 
limitations in the data available a modified Charlson index was used (Table 1). Scores were 
calculated from both case-note reviewCNR and administrative data. For pragmatic reasons, 
a five-year restriction on the look-back period of administrative data was applied (based 
upon findings of a previous study)28 whilst there was no restriction for the case-note 
reviewCNR. As renal disease was the condition of interest in this cohort it was not included 
as is the widely adopted convention when calculating the Charlson index.5,29-32   
 
Statistical Analysis 
The primary outcome of interest was all-cause mortality at six years. Secondary outcomes of 
interest were all-cause mortality at one and five years and the initiation of RRT.  
The baseline characteristics were summarised. Agreement between Charlson categories 
derived from the two data sources was assessed by the weighted Kappa with sub-group 
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analysis by gender, age group and CKD stage. The individual patient differences between 
Charlson scores from the two data sources were calculated. 
Poisson regression modelling was used to assess the association between Charlson scores 
and each outcome as the data did not meet the assumptions of proportional hazards for Cox 
regression. Models were unadjusted, partially adjusted (for age, sex, CKD stage at index and 
baseline proteinuria status) and fully adjusted (for these factors plus deprivation and 
smoking status). A Charlson score of 0 was the reference group. Results were presented as 
incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for each Charlson index 
category.  
Net reclassification improvement (NRI) compared the data sources for predicting all-cause 
mortality and initiation of RRT. Significance was set at the 5% level. Tables were produced 
which cross-tabulated the two data sources on the basis of low, medium and high risk 
categories of Charlson score (scores of 0, 1 to 3 and 4 and over respectively). The Tables 
were produced separately for those with and without an event (e.g. those who died and 
those who did not die). NRI compares how the two data sources classify individuals (on the 
basis that a good model will class individuals who suffer an event as high risk and those who 
do not suffer the event as low risk).  The reclassification of risk by one data source 
compared to another (e.g. lower risk class in those who do not suffer an event) is quantified 
to allow assessment as to which data source is superior at classifying risk of the outcome.33 
NRI compares two models using reclassification tables with different risk categories. In this 
study the models were the two different data sources and the risk categories were Charlson 
. Tables are produced separately for those with and without an event and the NRI process 
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then quantifies the correct movement within risk categories (which should be upwards for 
those with events and downwards for those with non-events). For both events and non-
events, the proportion where reclassification worsened using one model compared to the 
other is subtracted from the proportion where reclassification improved using the same 
comparison. The total NRI is derived from the difference between these two figures and 
gives an indication as to which model is superior at classifying the individuals according to 
the risk of the outcome.33 
All analyses were performed using Stata version 12.1 and Excel. Ethical approval for 
GLOMMS-1 and the comparison of comorbidity data sources has been given by the 
University of Aberdeen Research Ethics Committee and the NHS Grampian Caldicott 
Guardian. 
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Results   
Baseline data are available in supplementary Tables 1 to 3. The median age was 78.5 years, 
55.9% were female and 66.8% had stage three CKD. The highest Charlson score from both 
data sources was eight. Both sources classified most individuals as having Charlson scores of 
2 or less. The majority of patients (72.9%) had administrative data scores within plus or 
minus one point of their case-note reviewCNR data scores. Case-note reviewCNR scores 
were generally higher than administrative data scores.  
There was moderate agreement between the two data sources for the whole cohort 
(weighted Kappa 0.41) (supplementary Table 4). Agreement decreased in the older age 
groups from 0.58 in 15-54 year olds to 0.37 in 75-84 year olds and 0.38 in the 85 years and 
over group. Additional analysis (supplementary Table 5) showed the same pattern when 
smaller age categories were used. Agreement for CKD stage five was higher than for stages 
three and four (0.58 compared to 0.41 and 0.40 respectively). Additional analysis 
(supplementary Table 6) demonstrated that more of those with CKD stage five were older 
(76 out of the 90 individuals were aged 55 or over). 
By one year 22.1% had died and by six years 61.2% had died and 5.0% had started RRT 
(Table 2). Survival curves for six-year mortality by Charlson index scores derived from each 
data source showed a consistent pattern of lower survival with higher Charlson scores from 
both data sources (Figure 1). 
Poisson regression results are reported in Table 2 (partially adjusted models are available in 
supplementary Table 7 and five-year mortality is available in supplementary Table 8). In the 
unadjusted model for six-year mortality, the IRRs from case-note reviewCNR data increased 
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from 1.76 (95% CI 1.52-2.04) for a Charlson score of 1 to 3.51 (2.89-4.26) for a score of 5 and 
over.  The IRRs from administrative data in the same model increased from 1.67 (1.48-1.88) 
for a score of 1 to 3.94 (3.20-4.87) for a score of 5 and over. This pattern of higher IRRs with 
higher Charlson scores was also observed for one-year mortality and five-year mortality and 
this trend was unchanged within the partially and fully adjusted models for all mortality 
outcomes. The IRRs generated from the two data sources were of similar magnitude to each 
other in all models.  
The IRRs for initiating RRT were less than one for Charlson scores above 0. In the unadjusted 
model, these IRRs were statistically significantly reduced for all case-note reviewCNR 
Charlson index subgroups and for some administrative data subgroups. Adjusted models 
demonstrated no statistically significant association with RRT (Table 2). 
NRI is reported in Table 3 (five-year mortality available in supplementary Table 89). For all 
mortality outcomes, the administrative data models were significantly better at classifying 
the risk of death than the CNR models. For six-year mortality for example, the use of 
administrative data yielded an overall NRI of 0.053 (95% CI 0.024-0.082). This was 
statistically significant with a positive z score (2.4), p<0.05. For RRT the administrative data 
model was marginally better at classifying RRT risk than the CNR model, but this was not 
statistically significant (z= 1.0, p=0.3).  
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Discussion 
Interpretation of findings 
There was moderate agreement between the data sources. Administrative data scores were 
generally lower than case-note reviewCNR scores, consistent with the findings of a number 
of other studies.4,5,20 and a systematic review.  Previous work using the GLOMMS-1 cohort by 
Soo et al examined agreement between individual comorbidities, finding at least moderate 
agreement for most and that the prevalence of all comorbidities was higher based on CNR 
compared with administrative data.34 Our findings may relate to the restriction of the 
administrative data look-back period to five years, whilst there was no restriction on the 
look-back period for case-note reviewCNR. This is a limitation but is an approach similar to 
that taken by others. 
Agreement was better for younger age groups and those with more severe CKD, however 
these groups contained small numbers. Age did not appear to affect the association as more 
of those with stage five CKD at the index date were older. Soo et al found the prevalence of 
the majority of Charlson comorbidity conditions to be higher in those aged over 75.34 Better 
agreement in younger individuals may therefore reflect that coders had less conditions to 
code for on hospital discharge and so are more likely to capture all relevant conditions. 
The association of the Charlson index with mortality is unsurprising given that the Charlson 
index was originally developed to predict mortality.9 and The Charlson index has also been 
found to predict mortality in a number of renal studies.14-17 However, it is surprising that 
administrative data classified the risk of death better than case-note review data, 
particularly given the restriction in look-back period for administrative data. Tto the best of 
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our knowledge, no previous studies have reported administrative data to be superior to 
case-note reviewCNR when calculating the Charlson index. Previous studies of other disease 
conditions and in other countries have found either little difference between the two data 
sources for predicting mortality outcomes,5,13,22,35 or that Charlson scores derived from case-
note reviewCNR scores were superior to those derived from administrative data scores.21,32 
However,, we cannot be certain of the impact of our use of a modified version of the 
Charlson. Additionally, it should be highlighted that the IRRs generated during Poisson 
regression from the two data sources were of similar magnitude. Therefore in this context 
the results from NRI should not be over-interpreted.   
One explanation for our finding that administrative data are at least comparable to case-
note reviewCNR data, if not superior, could be that health conditions which lead to 
admission are more favourably identified by administrative data. These active conditions 
may be more severe and more likely to lead to death. Case-note review data may detect 
more conditions but, as the Charlson index does not assess disease severity, these may be 
conditions at a level not severe enough to impact upon mortality. As described below, the 
issue could also be due to the manner in which case-note review data were collected with 
the potential for measurement bias due to two different individuals recording the data. 
The unadjusted (but not the adjusted) results suggested that having any comorbidity 
decreased the likelihood of receiving RRT. However, an explanation for this is that those 
with a high burden of comorbid disease may not survive to initiate RRT or may choose a 
more conservative management course. A reason why the adjusted results were not 
significant is that the models were adjusted for CKD stage and proteinuria, both of which are 
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associated with the instigation of RRT.27 In addition the number of individuals receiving RRT 
was small and confidence intervals wide.  
 
Strengths and limitations 
Our study has a number of important strengths. The Charlson is a commonly used 
comorbidity index which, despite having been developed in a different population,  has 
been extensively used in many different populations including renal populations.14-17 As well 
as being the largest study of its kind in a chronic disease population, only one previous study 
has compared Charlson scores derived from the two data sources using a renal population 
and this was a small population (n=134) of dialysis patients with the outcome of mortality.25  
CKD is a chronic condition with high associated comorbidity and mortality, which thus places 
a substantial burden on both individuals and the healthcare system.26 Our findings in 
relation to patients with CKD may well therefore apply to other chronic conditions. As the 
cohort was identified from electronic laboratory records, there was a low risk of 
participation bias. The large study allowed for the identification of statistically significant 
differences and potentially wider generalizability. A number of important potential 
confounding factors were included within the regression models. The partially adjusted 
model showed the impact of factors previously shown to be important predictors of 
outcome in CKD,27 whilst the fully adjusted model included factors which may be of wider 
interest to practitioners and researchers. Despite this however, there was little difference 
between the partially and fully adjusted models. 
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Our study used NRI to assess model performance. This has an advantage compared to the 
previously widely used approach of area under the receiver operating-characteristic curve. 
This latter approach requires very strong associations of the variable of interest with the 
outcome in order to produce a statistically significant area under the curve. This is not an 
issue for NRI.33 NRI is a relatively new technique which has been widely used since it was 
proposed. However, there is still debate regarding its use and care needs to be taken when 
describing and interpreting NRI.36 We have described our methodology and also presented 
component parts of the NRI as proportions and percentages to aid interpretation. 
Our study has some important limitations. As the case-note reviewCNR data for the 
GLOMMS-1 study were not originally collected for the primary purpose of calculatingfor the 
Charlson index scores, some Charlson conditions were not available for inclusion and we 
therefore calculated a modified Charlson index score. Furthermore, the ICD-10 codes used 
within the administrative data did not identically match the recommended ICD-10 codes 
detailed in ICD-10 adaptations of the Charlson index.37 Some of the higher scoring Charlson 
conditions were not included (“Metastatic solid tumour” and “Acquired Immunodeficiency 
Syndrome (AIDS)”. However, it is not likely that this has altered our findings significantly. 
These conditions have a fairly low prevalence in previous renal studies, even when Human 
Immunodeficiency Virus (HIV) is used instead of AIDS (between 0.5% and 1.6% for 
“metastatic solid tumour” and between 0.0% and 0.4% for “AIDS/HIV”).15,38 In addition the 
prevalence of HIV amongst the Grampian population is very low (501 HIV reports in NHS 
Grampian between 1990 and 2011).39 Nonetheless, whilst our findings provide important 
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support for the use of administrative data in comorbidity scores, it is important to be aware 
we have used a modification of the Charlson comorbidity score. 
Despite this limitation, as Tthe same index was used for both data sources, so while the 
strength of association with outcomes might be affected (although the results suggest it 
worked well)it would not affect the aim of the study which was to compare the data 
sources.  
Original Charlson weights do not necessarily adequately represent the risk of the outcomes 
in this study, however, as described earlier, the original Charlson weights have been used 
widely since it was created and have been shown to be applicable in many different 
populations and for a range of outcomes.4,10-17 
The case-note reviewCNR data were not double data extracted, although a third individual 
did check a sample of both data extractions. As described earlier, tThere was a restriction on 
the look-back period for the administrative data but not for the case-note reviewCNR data. 
However, although this could be seen as disadvantaging administrative data, it still 
performed well despite this indicating the restricted look-back period (carried out for 
pragmatic reasons) was reasonable.  
The administrative data request timescale was based upon a study which  found that 
shorter look-back periods (of around one year) were sufficient for modelling post-
hospitalisation mortality but that looking back five years improved modelling for 
readmission outcomes.28 However, future research could clarify the optimal look-back 
timescale for hospital administrative data, particularly for non-mortality outcomes which 
are generally less commonly studied. 
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Conclusion 
The use of administrative data within patient care is becoming more prominent with the 
development of electronic patient records. Comorbidity measurement can be used to 
inform tools which can identify patients at high risk of hospital readmissions and mortality. 
This can enable the targeting of care which can reduce costs and burden to the individual 
and the health care system.  Accurate comorbidity adjustment is also important with the 
increasing emphasis upon comparing the outcomes of hospitals and units using league 
tables.40 Another use is in research, for example to adjust for the confounding effect of 
comorbidity.  
This study demonstrated that, whilst agreement between modified Charlson index scores 
derived from case-note reviewCNR and routine hospital administrative data may only be fair 
to moderate, administrative data are at least comparable if not superior when used to 
predict mortality outcomes. The modified Charlson index was not associated with the risk of 
commencing RRT. This research indicates the feasibility of using routinely collected data 
with a commonly used comorbidity index and is therefore an important contribution to 
comorbidity research. 
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Key points 
 Administrative data compared favourably and may be superior to case-note review 
when used in a modified Charlson comorbidity index to predict mortality in those with 
chronic kidney disease.  
 Neither data source was associated with commencing renal replacement therapy. 
 Accurately assessing comorbidity is a key public health consideration due to increasing 
emphasis upon adjusting for comorbidity when comparing healthcare institutions and 
upon identifying and managing high risk individuals. 
 This work concludes it is reasonable to use administrative data rather than carrying out 
the more resource intensive process of case-note review when assessing comorbidity. 
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Table 1: Comparison of original Charlson index to modified Charlson index used in this study   
Original Charlson comorbidity index   Modified Charlson comorbidity index  a 
Comorbid condition Weight 
 
Comorbid condition Weight 
Myocardial infarct 1 
 
Ischemic heart disease b 1 
Congestive heart failure 1 
 
Congestive heart failure 1 
Peripheral vascular disease 1 
 
Peripheral vascular disease 1 
Cerebrovascular disease 1 
 
Cerebrovascular disease 1 
Dementia 1 
 
Dementia 1 
Chronic pulmonary disease 1 
 
Chronic obstructive pulmonary disease c 1 
Mild liver disease 1 
 
Chronic Liver Disease d 1 
Connective tissue disease 1 
 
Connective tissue disease 1 
Diabetes with end-organ damage 2 
 
Diabetes 2 
Any tumour 2 
 
Non-haematological malignancy 2 
Leukaemia 2 
 
Haematological malignancy e 2 
Lymphoma 2 
Diabetes without chronic 
complication 1 
 
Not scored 
Moderate/severe renal disease 2 
 
Not scored 
Moderate/severe liver disease 3 
 
Not scored 
Ulcer disease 1 
 
Not available 
Hemiplegia 2 
 
Not available 
Metastatic solid tumour 6 
 
Not available 
AIDS 6   Not available 
 
Abbreviations: AIDS, Acquired immunodeficiency syndrome 
a Most of the case-note review data were sourced from events occurring prior to the index date, as per convention when calculating Charlson index 
scores. The exception was ischemic heart disease. Therefore the administrative data were made comparable to this. 
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b It was not possible to separate out myocardial infarction from other forms of ischemic heart disease in the case-note review. The  administrative data 
were made comparable 
c Only chronic obstructive pulmonary disease was available from case-note review. The  administrative data were made comparable 
d Only one option for liver disease was available from the case-note review. A cautious approach was taken and it was assigned a score of 1. 
e Leukaemia and lymphoma are not available individually from the case-note review and instead all forms of haematological malignancy were combined. 
The administrative data were made comparable. 
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Table 2: Outcomes by Charlson index score and unadjusted and fully adjusted models for each outcome  
  
CCI 
 Score 
Numbers Unadjusted Fully adjusted b 
CNR data SMR01 CNR data SMR data CNR data SMR data 
No event Event No event Event IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
n (%) n (%) n (%) n (%)   
Six year 
mortality 
0 430 
(57.5) 
318 
(42.5) 
695 
(52.3) 
635 
(47.7) 
1.00  
(reference) 
1.00  
(reference) 
1.00  
(reference) 
1.00  
(reference) 
1 286 
(38.9) 
449 
(61.1) 
240 
(35.2) 
442 
(64.8) 
1.76  
(1.53-2.04) 
1.67  
(1.48-1.88) 
1.43  
(1.24-1.65) 
1.47  
(1.30-1.66) 
2 306 
(35.6) 
554 
(64.4) 
220 
(32.1) 
466 
(67.9) 
1.94  
(1.70-2.23) 
1.85  
(1.64-2.08) 
1.84  
(1.60-2.12) 
1.73  
(1.53-1.95) 
3 177 
(31.9) 
378 
(68.1) 
109 
(29.0) 
267 
(71.0) 
2.20  
(1.89-2.55) 
2.02  
(1.75-2.33) 
2.13  
(1.83-2.48) 
1.93  
(1.66-2.23) 
4 82 
(26.8) 
224 
(73.2) 
36 
(18.4) 
160 
(81.6) 
2.56  
(2.16-3.03) 
2.83  
(2.38-3.36) 
2.48  
(2.08-2.96) 
2.77  
(2.31-3.31) 
5+ 30 
(16.9 
148 
(83.1) 
11 
(9.8) 
101 
(90.)2 
3.51  
(2.89-4.26) 
3.94  
(3.20-4.87) 
2.86  
(2.34-3.50) 
3.72  
(2.99-4.63) 
Total 1311 
(38.8) 
2071 
(61.2) 
1311 
(38.8) 
2071 
(61.2) 
 
One year 
mortality 
0 673 
(90.0) 
75 
(10.0) 
1175 
(88.3) 
155 
(11.7) 
1.00  
(reference) 
1.00  
(reference) 
1.00  
(reference) 
1.00  
(reference) 
1 582 
(79.2) 
153 
(20.8) 
522 
(76.5) 
160 
(23.5) 
2.25  
(1.71-2.97) 
2.16  
(1.73-2.70) 
1.94  
(1.46-2.57) 
1.86  
(1.49-2.33) 
2 653 
(75.9) 
207 
(24.1) 
504 
(73.5) 
182 
(26.5) 
2.58  
(1.98-3.36) 
2.53  
(2.04-3.13) 
2.55  
(1.94-3.34) 
2.42  
(1.95-3.01) 
3 404 
(72.8) 
151 
(27.2) 
259 
(68.9) 
117 
(31.1) 
2.97  
(2.25-3.91) 
3.03  
(2.38-3.85) 
3.12  
(2.34-4.15) 
3.16  
(2.47-4.04) 
4 217 
(70.9) 
89 
(29.1) 
116 
(59.2) 
80 
(40.8) 
3.31  
(2.43-4.50) 
4.13  
(3.15-5.41) 
3.58  
(2.60-4.93) 
4.51  
(3.41-5.96) 
5+ 106 
(59.6) 
72 
(40.4) 
59 
(52.7) 
53 
(47.3) 
4.87  
(3.52-6.73) 
4.99  
(3.65-6.81) 
4.66  
(3.32-6.53) 
5.01 ( 
3.62-6.95) 
Total 2635 
(77.9) 
747 
(22.1) 
2635 
(77.9) 
747 
(22.1) 
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Commencing 
RRT 
0 682 
(91.2) 
66 
(8.8) 
1238 
(93.1) 
92 
(6.9) 
1.00  
(reference) 
1.00  
(reference) 
1.00  
(reference) 
1.00  
(reference) 
 1 713 
(97.0) 
22 
(3.0) 
662 
(97.1) 
20 
(2.9) 
0.34  
(0.21-0.56) 
0.43  
(0.27-0.70) 
0.92  
(0.54-1.58) 
0.63  
(0.39-1.05) 
 2 820 
(95.3) 
40 
4.7) 
654 
(95.3) 
32 
(4.7) 
0.54  
(0.36-0.80) 
0.69  
(0.46-1.03) 
0.89  
(0.58-1.35) 
0.76  
(0.50-1.15) 
 3 532 
(95.9 
23 
(4.1 
362 
(96.3 
14 
(3.7 
0.48  
(0.30-0.77) 
0.55  
(0.31-0.97) 
0.92  
(0.54-1.55) 
0.80  
(0.45-1.44) 
 4 292 
(95.4) 
14 
(4.6) 
191 
(97.4) 
5 
(2.6) 
0.53  
(0.30-0.95) 
0.38  
(0.16-0.94) 
1.11  
(0.59-2.08) 
0.45  
(0.18-1.13) 
 5+ 173 
(97.2) 
5 
(2.8) 
105 
(93.8) 
7 
(6.3) 
0.33  
(0.13-0.82) 
0.95  
(0.44-2.05) 
0.74  
(0.28-1.94) 
0.94  
(0.42-2.08) 
  Total 3212 
(95.0) 
170 
(5.0) 
3212 
(95.0) 
170 
(5.0)   
 
Abbreviations: CCI, Charlson comorbidity index; CNR, Case-note review; SMR01, Scottish Morbidity Record 01; IRR, incidence rate ratio; CI, Confidence 
Interval 
a. Partially adjusted for age, sex, CKD stage at index and baseline proteinuria status 
b. Fully adjusted for age, sex, CKD stage at index, baseline proteinuria status, the Scottish Index of Multiple Deprivation and smoking status  
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Table 3: Net reclassification improvement for each outcome by Charlson index score risk categories a   
    6 year mortality       1 year mortality     RRT     
CNR 
Score 
 
SMR01 score     
 
SMR01 score     
 
SMR01 score   
  0 1 to 3 4+ Total  0 1 to 3 4+ Total  0 1 to 3 4+ Total  
 
Died 
    
Died 
    
Yes 
    
0 
 
215 101 2 
  
36 37 2 
  
58 8 0 
 
1 to 3 
 
377 900 104 
  
105 355 51 
  
29 52 4 
 
4+ 
 
43 174 155 
  
14 67 80 
  
5 6 8 
 
Total 
    
2071 
    
747 
    
170 
                
Total proportion where classification improved 
using SMR 
207/2071 (10.0%) 
  
90/747 (12.0%) 
 
12/170 (7.1%) 
Total proportion where classification worsened 
using SMR 
594/2071 (28.7%) 
  
186/747 (24.9%) 
 
40/170 (23.5%) 
Net gain in reclassification proportion 
for event  
-0.187 (18.7%) 
   
-0.129 (12.9%) 
  
-0.164 (16.4%) 
                
 
Alive 
    
Alive 
    
No 
    
0 
 
368 62 0 
  
547 126 0 
  
525 155 2 
 
1 to 3 
 
311 440 18 
  
583 985 71 
  
659 1288 118 
 
4+ 
 
16 67 29 
  
45 174 104 
  
54 235 176 
 
Total 
    
1311 
    
2635 
    
3212 
                
Total proportion where classification improved 
using SMR 
394/1311 (30.1%) 
  
802/2635 (30.4%) 
 
948/3212 (29.5%) 
Total proportion where classification worsened 
using SMR 
80/1311 (6.1%) 
  
197/2635 (7.5%) 
 
275/3212 (8.6%) 
Net gain in reclassification proportion for no 
event 
0.24 (24.0%) 
   
0.229 (22.9%) 
  
0.209 (20.9%) 
 27 
 
                
Total net reclassification improvement (95% CI) 0.053 (0.024,0.082) 
 
0.102 (0.072,0.130) 
 
0.045 (-0.020,0.095) 
                
Z -Total 
     
2.4 
   
4 
    
1 
2-tailed P *     
 
 0.01 
 
  <0.0001        0.31 
 
 a Correct reclassifications are shaded in light grey and incorrect reclassifications are shaded in dark grey. 
Abbreviations: CNR, Case-note review; SMR01, Scottish Morbidity Record 01. 
* P-value <0.05. 
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Figure 1: Kaplan Meier survival estimates for 6 year mortality by Charlson comorbidity index scores derived from case-note review and administrative data 
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Abbreviations: CCI, Charlson comorbidity index; SMR01, Scottish Morbidity Record 01. 
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